Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine

Pharmacotherapy

Volumn 27, Issue 10, 2007, Pages 1440-1445

  Whitley, Heather P ^a,b   Moorman, Krystal L ^c  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c Kaiser Permanente Colorado Region ^*  (United States)

Author keywords

Amphetamine; Brain; CNS; Dextroamphetamine; Dopamine; Drug interaction; Nicotine; Pharmacodynamics; Smoking cessation; Tobacco; Varenicline

Indexed keywords

AMPHETAMINE; IBUPROFEN; VARENICLINE;

ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; MIGRAINE; OUTCOME ASSESSMENT; PRESCRIPTION; SMOKING; SMOKING CESSATION; SYMPTOM;

ADOLESCENT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; MALE; QUINOXALINES; RECURRENCE; SMOKING; SMOKING CESSATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 34948846642     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.10.1440     Document Type: Article

References (27)

1. 2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296:47-55.
2. 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006;296:56-63.
3. Benowitz NL. Cigarette smoking and nicotine addiction. Med Clin North Am 1992;76(2):415-37.
4. Henningfield JE, Stapleton JM, Benowitz ML, Garyson RF, London ED. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993;33(1):23-9.
5. McClure JB, Swan GE. Tailoring nicotine replacement therapy: rationale and potential approaches. CNS Drugs 2006;20(4):281-91.
6. Cousins MS, Stamat HM, de Wit H. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology 2001;157:243-53.
7. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006;60(5):571-6.
8. Johnson BA. New weapon to curb smoking. Arch Intern Med 2006;166:1547-50.
9. 2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7.
10. Pfizer Labs. Chantix (varenicline) package insert. New York, NY; 2006.
11. World Health Organization. Leave the pack behind: world no-tobacco day. World Health Organization. May 1999. Available from http://ltdlimages.library. ucsf.edu/imagesr/r/z/t/rzt83c00/Srzt83c00.pdf. Accessed November 27, 2006.
12. Micromedex. Micromedex healthcare series [electronic version]. Greenwood Village, CO: Thomson Micromedex. Available from http://www.thomsonhc.com. Accessed March 12, 2007.
13. Kelley AE. Nicotine receptors: addiction's smoking gun? Nat Med 2002;8(5):447-9.
14. Alsene KM, Mahler SV, deWit H. Effects of d-amphetamine and smoking abstinence on cue-induced cigarette craving. Exp Clin Psychopharmacol 2005;13(3):209-18.
15. MD Consult. Varenicline drug monograph. Available from http://home.mdconsult.com/das/pharm/view/68283630-2. Accessed February 12, 2007.
16. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002;53:606-17.
17. Schoffelmeer AN, De Vries TJ, Wardeh G, van de Ven HWM, Vanderschuren LJMJ. Psychostimulant-induced behavioral sensitization depends on nicotinic receptor activation. J Neurosci 2002;22(8):3269-76.
18. Chait LD, Griffiths RR. Effects of caffeine on cigarette smoking and subjective response. Clin Pharmacol Ther 1983;34:612-22.
19. Henningfield JE, Griffiths RR. Cigarette smoking and subjective response: effects of d-amphetamine. Clin Pharmacol Ther 1981;30:497-505.
20. Kelly TH, Foltin RW, Fischman MW. The effects of repeated amphetamine exposure on multiple measures of human behavior. Pharmacol Biochem Behav 1991;38:417-26.
21. Schuster CR, Lucchesi BR, Emley GS. The effects of d-amphetamine, meprobamate, and lobeline on the cigarette smoking behavior of normal human subjects. NIDA Res Monogr 1979;23:91-9.
22. Tidey JW, O'Neill S, Higgins ST. d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology 2000;153:85-92.
23. Dani JA, DeBiasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001;70:439-46.
24. Shoaib M. Is dopamine important in nicotine dependence? J Physiol 1998;92:229-33.
25. Stryer L, ed. Enzymes: basic concepts and kinetics. In: Biochemistry, 4th ed. New York: WH Freeman and Company, 2000:196-8.
26. Roll JM, Higgins ST, Tidey J. Cocaine use can increase cigarette smoking: evidence from laboratory and naturalistic settings. Exp Clin Psychopharmacol 1997;5:263-8.
27. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation. JAMA 2006;296:64-71.